Washington D.C. – The United States Congress successfully navigated intense fiscal deadlines this past week, culminating in the passage of a critical government funding package that secured essential healthcare programs and averted a potential shutdown. Simultaneously, significant developments unfolded regarding nominations for pivotal health agency leadership roles, while federal health administrators initiated notable shifts in healthcare payment and delivery model experiments.
Congressional Action Secures Healthcare Funding
Legislative leaders in Congress worked diligently to meet the March 14th deadline set to fund government operations and prevent a disruptive shutdown. The culmination of these efforts was the passage of a fiscal year 2025 funding package. The House of Representatives approved this measure by a vote of 217-213 on March 11, 2025, sending it forward for further action. A crucial element of this package for the healthcare sector was the extension of several expiring health provisions, commonly referred to as “extenders.”
These extended provisions include vital flexibilities for Medicare telehealth services, which have become increasingly important in expanding access to care, particularly since the pandemic began. The package also ensured continued essential payments for Medicare Dependent Hospitals and Low-Volume Hospitals. These hospital classifications typically serve rural and underserved communities, where they often represent the primary or sole source of local healthcare. The funding package successfully extended these critical programs through September 30th, providing stability for patients and providers alike over the coming months.
Navigating Health Agency Nominations
Parallel to the legislative funding process, the confirmation processes for nominees slated to lead key federal health agencies continued to advance, albeit with some significant shifts. The administration saw movement on several fronts regarding individuals tapped for crucial roles influencing public health policy and healthcare administration.
One notable development involved the position of Director for the Centers for Disease Control and Prevention (CDC). The White House opted to withdraw the nomination of Dr. Dave Weldon for the role. Reports indicated that the withdrawal was reportedly due to past statements on vaccine safety and autism, a sensitive topic further amplified amid the current measles situation which has seen outbreaks in various parts of the country. The leadership of the CDC is considered paramount in guiding the nation’s response to infectious diseases and other public health threats.
Attention also focused on the nomination of Dr. Mehmet Oz for the position of Administrator of the Centers for Medicare & Medicaid Services (CMS). Dr. Oz participated in a hearing before the Senate Finance Committee on March 14, 2025, as part of his confirmation proceedings. During his testimony, Dr. Oz reportedly expressed support for the Medicare Advantage program, the private plan alternative to traditional Medicare. He also signaled backing for greater implementation of health technologies, specifically mentioning the potential benefits of telehealth and AI in improving healthcare delivery and efficiency within the vast federal healthcare programs overseen by CMS.
CMS Reshapes Innovation Model Portfolio
Adding another layer to the week’s healthcare news, CMS announced a strategic decision regarding its portfolio of experimental payment and service delivery models. On March 12, 2025, the agency publicly confirmed the early termination of several CMS Innovation Center (CMMI) models.
CMMI is tasked by Congress with testing innovative approaches to pay for and deliver healthcare in Medicare, Medicaid, and the Children’s Health Insurance Program (CHIP) with the goal of improving quality while lowering costs. The models marked for early termination include the Maryland Total Cost of Care Model, which was originally scheduled to run through 2026 and intended to transition to the AHEAD model in January 2026. The Primary Care First model, designed to test payment reforms in primary care settings, was also on the list. Additionally, the ESRD Treatment Choices (ETC) Model, focused on care for individuals with End-Stage Renal Disease, and the Making Care Primary model (2024-2034), a multi-payer initiative intended to support advanced primary care, were included in the early terminations. The decision to end these models prematurely signals a potential re-evaluation or shift in the agency’s innovation strategy.
A Week of Policy and Administrative Shifts
The past week underscored the dynamic nature of US healthcare policy, characterized by critical legislative deadlines, high-stakes personnel decisions, and administrative recalibrations. Congress’s action ensures the immediate stability of key programs relied upon by millions of Americans and healthcare providers. Meanwhile, the developments surrounding leadership nominations highlight the political and substantive considerations shaping the future direction of federal health agencies. Concurrently, CMS’s decision to wind down certain innovation models indicates an ongoing process of refining strategies aimed at transforming healthcare delivery and payment across the nation. These interwoven events collectively mark a period of significant consequence for the landscape of American healthcare.
